131I-labelled-iodized oil for palliative treatment of hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 905-910

  Borbath, Ivan ^a   Lhommel, Renaud ^a   Bittich, Laila ^a   Goffette, Pierre ^a   Annet, Laurence ^a   Van Beers, Bernard E ^a   Bonny, Marie Alix ^a   Pauwels, Stanislas ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Carcinoma; Hepatocellular; Lipiodol; Palliative treatment; Radiotherapy

Indexed keywords

IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; UNCLASSIFIED DRUG; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DRUG INDICATION; FEMALE; FEVER; HUMAN; INTERSTITIAL PNEUMONIA; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; MORTALITY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME; VALIDATION PROCESS; CANCER STAGING; EVALUATION; LIVER; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 23944474578     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00004     Document Type: Article

References (28)

1. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Tabor E (editor): Liver Cancer. New York: Churchill, Livingstone; 1997, pp. 13-28.
2. De Vos-Irvine H, Goldberg D, Hole D, McMenamin J. Trends in primary liver cancer. Lancet 1998; 351:215-216.
3. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
5. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
6. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
7. de Baere T, Taourel P, Tubiana JM, Kuoch V, Ducreux M, Lumbroso J, Roche AJ. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 1999; 212:665-668.
8. Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
9. Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31:840-845.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2000; 5:421-430.
11. Raoul JI, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer 1992; 69:346-352.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261.
14. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
15. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.
16. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353:797-801.
17. Boucher E, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003; 38: 1237-1241.
18. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76:2202-2210.
19. Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35:1313-1318.
20. Maini CL, Scelsa MG, Fiumara C, Tofani A, Sciuto R, Tipaldi L, et al. Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma. Clin Nucl Med 1996; 21:221-226.
21. Brans B, De Winter F, Defreyne L, Troisi R, Vanlangenhove P, Van Vlierberghe H, et al. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 16:333-338.
22. Brans B, Bacher K, Vandevyver V, Vanlangenhove P, Smeets P, Thierens H, et al. Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-lipiodol delivery on tumour uptake and response. Nucl Med Commun 2003; 24:391-396.
23. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266-2273.
24. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50:881-885.
25. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization; 1979.
26. Prasad SR, Saini S, Sumner JE, Hahn PF, Sahani D, Boland GW. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr 2003; 27:380-384.
27. Preketes A, Boyd S, Cooper D, McKay S, Smart RC, Qulnn R. Pulmonary toxicity following lipiodol I-131 treatment for liver tumours. Reg Cancer Treat 1996; 9:21-26.
28. Volatron AC, Le Garff G, Guillot S, Polard E, Mesner M. Pneumopathies secondary to the injection of radioactive lipiodol or lipiocis [in French]. Rev Malad Respir 2003; 20:128-135.